When Laura Pearce learned that her breast cancer had returned, the situation was no longer the one she had faced several years earlier.
The disease had spread.
By 2023, Pearce was living with stage IV metastatic breast cancer involving her liver, bones and lungs. She has said that roughly 85% of her liver was affected and that at one point the outlook presented to her was measured in weeks rather than years.
For a mother of six, the implications were devastating.
What happened next would eventually cost her more than £100,000 and consume money she had expected to use much later in life. Pearce began travelling from the UK to Germany for a procedure known as transarterial chemoembolization, or TACE, followed later by microwave ablation.
By September 2024, according to accounts of her case, scans were no longer showing active metastatic disease.
It is an extraordinary outcome.
It is also a story that requires careful interpretation.
TACE is not an alternative cancer remedy, nor is it a secret treatment hidden from conventional medicine. It is an established interventional radiology technique with specific applications in cancer care.
The more interesting question, therefore, is not simply why Pearce received it.
It is why a treatment capable of producing encouraging results in selected patients is not appropriate for everyone with breast cancer that has spread to the liver.
Her first cancer diagnosis came years earlier
Pearce was initially diagnosed with breast cancer in 2018 and underwent conventional cancer treatment, including chemotherapy, radiotherapy and surgery.
The disease subsequently became undetectable.
But breast cancer can return years after the original diagnosis. When it spreads to a distant organ, the resulting tumour does not become a new type of cancer simply because it is growing somewhere else.
Breast cancer cells that spread to the liver, for example, remain breast cancer cells. The condition is therefore described as metastatic breast cancer involving the liver rather than primary liver cancer.
In Pearce’s case, the recurrence was discovered in 2023 after she experienced unusual exhaustion and discomfort or tightness around the liver area.
Investigations revealed extensive disease.
Cancer was present not only in her liver but also in her lungs and bones.
This is stage IV breast cancer.
The US National Cancer Institute explains that metastatic breast cancer occurs when cancer has spread beyond the breast and nearby lymph nodes to distant parts of the body. Common sites include the bones, lungs, liver and brain.
One word in this story is particularly easy to misunderstand: “palliative”
Some social-media versions of Pearce’s story reduce what happened to a striking contrast: the NHS had nothing left to offer, while doctors in Germany provided the treatment that saved her.
The reality is more complicated.
Pearce has described being offered palliative chemotherapy in Britain and receiving a cycle of treatment before developing neutropenic sepsis. She subsequently continued pursuing treatment in Germany.
This distinction matters because “palliative” does not necessarily mean that doctors have stopped treating cancer.
For someone with metastatic disease, treatment may be considered palliative because eliminating every cancer cell and achieving a permanent cure is unlikely. Yet treatment may still actively suppress the cancer, relieve symptoms and prolong life, sometimes for years.
Depending on the biology of a breast tumour, systemic options can include endocrine therapy, chemotherapy, targeted drugs and immunotherapy.
In other words, palliative cancer treatment and end-of-life care are not interchangeable terms.
The search that took her to Frankfurt
Pearce continued looking for other possibilities and eventually travelled to Frankfurt, where she was treated by Professor Thomas J. Vogl, a specialist in interventional radiology.
The procedure offered there was not an untested alternative therapy.
Vogl and colleagues have published research examining locoregional approaches, including TACE, for breast cancer metastases in the liver.
Pearce began travelling to Germany in 2023.
She has reported undergoing 11 TACE sessions over approximately 13 months, with microwave ablation also forming part of her treatment.
Financing it required extraordinary sacrifices.
She used pension money, savings and funds from her life insurance, while the cumulative expense of treatment and repeated travel reportedly exceeded £100,000.
How does TACE actually work?
TACE stands for transarterial chemoembolization.
Unlike conventional intravenous chemotherapy, which circulates throughout the body, TACE is designed to target tumours within a particular organ – most commonly the liver.
During the procedure, an interventional radiologist guides a thin catheter through the arterial system toward blood vessels supplying the tumour.
Cancer-fighting medication can then be delivered directly into the targeted area. Embolic material is also introduced to reduce or block blood flow to the tumour.
The strategy therefore combines two effects: exposing the tumour to a high local concentration of chemotherapy while simultaneously restricting its blood supply.
Cancer Research UK describes chemoembolization among the treatments that may be considered in selected cases of secondary cancer in the liver.
That distinction is important when discussing Pearce’s story.
TACE belongs to interventional oncology. It should not be grouped with unproven alternative cancer therapies simply because Pearce travelled privately to another country to receive it.
Why isn’t every patient with liver metastases offered TACE?
This is where an individual success story meets the much more complicated reality of cancer medicine.
Metastatic breast cancer is a systemic disease.
A treatment delivered to tumours in the liver does not automatically treat cancer cells elsewhere in the body.
If a patient has disease in the liver, lungs and bones, successfully treating the liver does not mean that the other metastatic sites have simultaneously been eliminated by the same procedure.
That is one reason systemic therapies remain central to the management of metastatic breast cancer.
Breast Cancer Now notes that local treatments can sometimes be considered for secondary breast cancer in the liver, but they treat disease at that particular site rather than cancer elsewhere in the body.
Whether a patient might benefit depends on numerous factors, including the amount of liver involved, liver function, the extent of disease outside the liver, previous treatments and overall health.
The question is therefore not simply whether TACE “works.”
It is whether it is likely to offer more benefit than risk to a particular patient at a particular stage of disease.
What does the research tell us?
Pearce’s experience is not the only evidence available.
Researchers have investigated intra-arterial therapies for breast cancer liver metastases, although the evidence remains much less extensive than that supporting standard systemic treatments.
A systematic review published in 2025 examined studies of TACE and another liver-directed treatment known as transarterial radioembolization, or TARE, in patients with breast cancer liver metastases.
Ten TACE studies involving a total of 462 patients were included.
Across those studies, the reported median local disease-control rate was approximately 68.7%, while median overall survival was approximately 15.3 months.
Those figures sound impressive, but they require context.
They do not mean that TACE gives a patient an additional 15.3 months of life.
The studies included different groups of patients who had undergone different previous treatments and received different treatment protocols. Their cancers also varied considerably.
The researchers considered the studies sufficiently heterogeneous that performing a conventional meta-analysis was not appropriate.
The evidence therefore suggests that intra-arterial therapies may provide meaningful disease control for selected patients.
It does not establish TACE as a universal treatment for breast cancer that has metastasized to the liver.
Pearce’s outcome appears remarkable even against that background
The reported result in Pearce’s case goes beyond simply slowing the growth of liver tumours.
Following repeated treatments and microwave ablation, subsequent imaging reportedly stopped showing active metastatic disease.
Pearce has continued to describe scans without evidence of active cancer while undergoing regular monitoring.
But this brings us to one of the most important distinctions in the entire story.
“No evidence of active disease” and “cured” are not the same statement
A dramatic headline can easily turn Pearce’s experience into a simple narrative:
Doctors said she was dying. She travelled to Germany. The cancer was cured.
Medicine requires more precision.
Stage IV breast cancer is generally regarded as treatable but extremely difficult to cure permanently. Some patients, however, can experience exceptionally deep responses and extended periods during which scans show no evidence of active disease.
That is an extraordinary result, but doctors remain cautious about describing it as a permanent cure.
Pearce herself has continued to refer to her history of stage IV metastatic breast cancer and the need for ongoing surveillance.
According to information she has shared publicly in 2026, she continues travelling to Germany for monitoring and reports having no current evidence of active metastatic disease.
That wording matters.
It acknowledges an exceptional response without claiming that recurrence has become impossible.
The road to that result was anything but easy
Short social-media posts can make the sequence appear deceptively straightforward: conventional treatment options ran out, Pearce found TACE, paid for it and the cancer disappeared.
Her experience was far more difficult.
She has described becoming severely unwell and losing considerable weight. Her medical journey also included serious complications such as sepsis, and she has discussed problems including ascites, the accumulation of fluid in the abdomen that can occur with severe liver disease.
TACE itself is not risk-free.
Patients may experience pain, fever, nausea and fatigue after treatment, collectively often referred to as post-embolization syndrome.
More serious complications can occur, including deterioration in liver function.
This is precisely why liver-directed procedures require careful patient selection and specialist assessment.
Does her outcome prove the NHS made the wrong decision?
It is an understandable question, but Pearce’s survival cannot by itself provide the answer.
Retrospective reasoning has a major limitation: today we know how her story unfolded.
Her doctors in 2023 did not.
A remarkable response in one patient does not establish that clinicians could have predicted that response beforehand or that the same approach would have been appropriate for another patient with apparently similar disease.
There is another complication.
Pearce’s cancer was not confined to her liver. She had disease at other metastatic sites, making systemic treatment an important part of the overall medical picture.
Nevertheless, her experience does raise a legitimate broader issue: how patients with unusually complex or advanced cancers gain access to multidisciplinary assessment, clinical trials and highly specialised locoregional procedures.
That is a much more useful question than framing the story as conventional medicine versus an overlooked cure.
Modern oncology has become extraordinarily specialised. A procedure available at one expert centre may not be available, recommended or appropriate at another.
Her complementary treatments require a separate conversation
Pearce has also publicly discussed dietary changes, supplements and other interventions she incorporated into her broader approach to cancer.
These should not be treated as equivalent to the medical procedures for which published clinical evidence exists.
There is research examining TACE and tumour ablation.
There is no evidence establishing that a particular supplement, detox regimen or dietary intervention caused Pearce’s remarkable response.
When someone receives several interventions simultaneously, improvement afterward cannot tell us which individual component was responsible.
A patient’s experience can generate useful questions for future research.
It cannot establish causation.
What her story can – and cannot – teach other cancer patients
Perhaps the most dangerous interpretation of Pearce’s experience would be that seriously ill patients should reject their doctors’ advice and search the internet for something different.
The opposite extreme is not particularly helpful either.
Second opinions exist for a reason.
For patients facing complex or advanced cancer, it can be reasonable to ask whether another specialist centre would reach the same conclusion, whether a clinical trial is available or whether a locoregional procedure might be appropriate.
Sometimes another specialist will confirm exactly what the first medical team recommended.
Sometimes an experimental treatment will carry more risk than realistic benefit.
Sometimes an expensive procedure will not work.
But occasionally, another specialist may identify an option that was not previously available or considered appropriate.
Seeking another expert opinion is not the same thing as abandoning evidence-based medicine.
It can be part of evidence-based medicine.
She spent the money saved for her future so that she might have one
There is a line from Pearce’s story that captures its human dimension better than any survival statistic.
She has described effectively spending the money she had put aside for her future in order to make sure she actually had a future.
The financial consequences did not disappear when her scans improved.
After using substantial amounts of her savings, pension and insurance money to finance treatment and monitoring, Pearce later turned to fundraising to help cover continued medical assessments and trips to Germany.
Years after the point at which she says doctors feared her remaining life might be measured in weeks, she is still here.
According to the latest information she has made public, there is currently no evidence of active metastatic disease.
That deserves to be recognised for what it is: an exceptional outcome.
But exceptional outcomes are not the same thing as universal evidence.
Cancer medicine advances by studying many patients, comparing treatments, identifying who benefits, documenting failures as well as successes and understanding the risks that accompany every intervention.
Laura Pearce’s experience therefore allows two statements to be true at once.
The liver-directed treatment she received in Germany was associated with an extraordinary outcome in her individual case.
Her experience does not prove that TACE can cure metastatic breast cancer in general.
Understanding that distinction does not make her story less remarkable.
It makes the story more truthful.
Sources and further reading
This article was developed using information from the US National Cancer Institute, the American Cancer Society, Cancer Research UK and Breast Cancer Now, together with peer-reviewed medical literature on transarterial chemoembolization and other intra-arterial treatments for breast cancer liver metastases.
The research reviewed includes studies indexed in PubMed and the 2025 systematic review examining TACE and TARE for breast cancer liver metastases.
Public accounts provided by Laura Pearce were also consulted for details concerning the timeline of her illness, treatment in Germany, subsequent monitoring and her reported current status.
Important medical disclaimer
This article is provided for informational purposes only. It is not medical advice and should not be interpreted as a recommendation or endorsement of TACE, microwave ablation or any other cancer treatment.
Laura Pearce’s experience represents the outcome of an individual patient and cannot predict how another person with cancer will respond to the same procedure.
Cancer diagnosis and treatment decisions should be made with qualified medical professionals. Patients should not stop, delay or change prescribed cancer treatment without discussing it with their oncology team.
Anyone interested in TACE, tumour ablation, clinical trials or other treatment possibilities should discuss their individual circumstances with an oncologist. When appropriate, patients may also choose to seek a second specialist medical opinion.